Entrada Therapeutics (TRDA) announced that the FDA has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 for the potential treatment of Duchenne
muscular dystrophy in adult patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping.
The global ELEVATE-44 program will cover a broad population of patients with DMD and support evaluation of ENTR-601-44 in patients with both early and advanced disease.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com